NEW YORK – Oncocyte said on Thursday that it has entered a distribution agreement with ProGenetics, expanding the commercial availability of its DetermaRx test to Israel. Financial and other terms were not disclosed.
DetermaRx is a treatment stratification test that identifies patients at high risk for lung cancer recurrence who may benefit from adjuvant chemotherapy after tumor removal surgery. Oncocyte launched the test in the United States through an early-access program in late January, which it said has now expanded to over 40 sites.
The distribution agreement with ProGenetics is Oncocyte's second this year, following a deal with Core Diagnostics in April to make DetermaRx available in India, the Middle East, and Africa.
In a statement, Oncocyte CEO Ron Andrews said that ProGenetics is a welcome partner in growing the reach of DetermaRx globally. "International expansion is central to Oncocyte’s strategy," he added.
Progenetics CEO Yoav Manaster added that he believes DetermaRx "will gain significant physician and patient adoption" in the region.